Novalgina (Metamizole Sodium)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production in both peripheral tissues and the central nervous system. This reduction dampens pain signaling pathways and resets the hypothalamic temperature set‑point, resulting in analgesic and antipyretic effects. It also influences central pain modulation mechanisms.

The appropriate dose of Novalgina is determined by the prescribing clinician based on the individual patient's condition, age, weight, and response to therapy. Healthcare providers consider factors such as the severity of pain or fever and any relevant comorbidities before establishing a dosing regimen.

The safety of metamizole sodium in pregnancy and lactation has not been definitively established. It is generally classified as a category where use is avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant or breastfeeding should discuss alternatives with their healthcare provider.

To order Novalgina, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Novalgina (metamizole sodium) belongs to the pyrazolone class, offering analgesic and antipyretic effects similar to NSAIDs but with a distinct mechanism that may provide rapid pain relief. Unlike opioids, it does not act on opioid receptors, reducing the risk of dependence. However, it carries a unique risk of agranulocytosis, which is less common with many NSAIDs.

Novalgina should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging to protect them from moisture and light. Do not store in areas with high humidity or extreme heat, and keep the product out of reach of children.

Novalgina is administered orally. The tablet should be swallowed whole with a glass of water, preferably after a meal to reduce gastrointestinal discomfort. The exact administration schedule and any required monitoring are determined by the prescribing clinician.

The most serious adverse reactions associated with Novalgina include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe skin reactions such as Stevens‑Johnson syndrome. Anaphylactic shock, though rare, can also occur. Patients should be instructed to seek immediate medical attention if they develop signs of infection, unexplained fever, rash, or breathing difficulties.

Novalgina should be avoided in individuals with known hypersensitivity to metamizole or other pyrazolones, patients with pre‑existing severe blood dyscrasias, and those who have experienced agranulocytosis with any medication. Caution is also advised for patients with severe liver or kidney impairment, and it is generally contraindicated during pregnancy unless no safer alternative exists.